Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILENYA vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
0.5 mg orally once daily, with or without food
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
The terminal elimination half-life of fingolimod is approximately 6–9 days (mean 8.4 days). Due to the prolonged half-life, steady-state is achieved after 1–2 months of daily dosing, and lymphopenia may persist for up to 2 months after treatment cessation.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Primarily metabolized by CYP4F2, and to a lesser extent by CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Extensive first-pass metabolism via reversible stereoselective phosphorylation to active metabolite fingolimod-phosphate; also undergoes oxidative metabolism. Elimination half-life is approximately 6-9 days.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Fingolimod is primarily eliminated via fecal excretion (81%) and to a lesser extent via renal excretion (<1% as unchanged drug). Biliary excretion accounts for a minor portion. The major metabolic pathway is via CYP4F2-mediated hydroxylation, followed by glucuronidation and elimination in feces.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Fingolimod is approximately 99.7% bound to plasma proteins, primarily to albumin and lipoproteins (including α1-acid glycoprotein). The main active metabolite, fingolimod-phosphate, is also highly bound (>99%).
10-25% bound to albumin at therapeutic concentrations.
The volume of distribution (Vd) is approximately 17 L/kg (range 7–30 L/kg), indicating extensive tissue distribution, especially into erythrocytes (about 20% of total drug in blood) and sequestration in central nervous system and lymphoid tissues.
0.8-1.0 L/kg. Indicates distribution into total body water.
Oral bioavailability is approximately 93% (range 84–98%). Absorption is not significantly affected by food, but to reduce the risk of bradycardia and atrioventricular block, the first dose should be taken in the morning after a low-fat or fat-free meal.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
No dose adjustment required for mild to severe renal impairment including dialysis; monitor patients with severe renal impairment for bradycardia at treatment initiation
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A and B) but initiate with caution and monitor liver enzymes
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Approved for pediatric patients aged 10 years and older: for body weight ≤40 kg, 0.25 mg orally once daily; for body weight >40 kg, standard adult dose of 0.5 mg orally once daily
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
No specific dose adjustment recommended; use with caution due to potential for decreased renal function and increased sensitivity to bradycardia, monitor heart rate and blood pressure
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for at least 6 hours, including hourly pulse and blood pressure measurement, and ECG before and after first dose. Risk of infections, including fatal cryptococcal infections and other opportunistic infections. Risk of macular edema, especially in patients with uveitis or diabetes mellitus. Risk of posterior reversible encephalopathy syndrome (PRES). Risk of cutaneous malignancies (basal cell carcinoma, melanoma, Merkel cell carcinoma). Risk of fetal harm; advise females of reproductive potential of potential risk and need for effective contraception.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Bradyarrhythmia: First-dose monitoring required; avoid in patients with sinoatrial block, sick sinus syndrome, second-degree or third-degree AV block unless pacemaker present.,Infections: Monitor for infections; consider suspending treatment if serious infection occurs. Vaccination against varicella zoster virus recommended before initiation.,Macular edema: Ophthalmologic evaluation before and 3-4 months after starting treatment; more frequent assessments in patients with diabetes or uveitis.,Respiratory effects: Dose-dependent decrease in forced expiratory volume and diffusion capacity; monitor pulmonary function if clinically indicated.,Elevated liver enzymes: Monitor liver enzymes before and during treatment; discontinue if significant liver injury occurs.,Fetal harm: Effective contraception required during and for 2 months after discontinuation.,Cutaneous malignancies: Baseline and routine dermatologic evaluations recommended.,Immune system effects: Avoid live attenuated vaccines during and for 2 months after treatment.,Posterior reversible encephalopathy syndrome (PRES): Evaluate rapidly if symptoms such as severe headache, altered mental status, visual disturbances, or seizures occur.,Increased blood pressure: Monitor blood pressure.,Reactivation of hepatitis B virus in carriers: Screen before initiation.,Tumor risk: Overall increased risk of malignancies, especially skin cancers and lymphomas.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hypersensitivity to fingolimod or any excipient,Recent myocardial infarction (within last 6 months),Unstable angina,Stroke or transient ischemic attack (within last 6 months),History of second-degree Mobitz type II or third-degree AV block, sick sinus syndrome, or sinoatrial block unless patient has an implanted pacemaker,Baseline QTc interval ≥500 msec,Treatment with Class Ia or Class III antiarrhythmics,Severe untreated sleep apnea,Concomitant use of pimozide
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
No significant food interactions reported; take with or without food. Avoid grapefruit juice? No known interaction.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at doses similar to human exposure). Second and third trimesters: limited human data; animal studies show reduced fetal weight and increased fetal mortality. Risk cannot be excluded; use only if benefit outweighs risk.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Not recommended during breastfeeding. Fingolimod is excreted in animal milk; unknown if excreted in human milk. M/P ratio not established. Potential for serious adverse reactions in nursing infants, including bradycardia, infections, and immunosuppression.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No established dose adjustment in pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, decreased protein binding) may reduce exposure; consider therapeutic drug monitoring if available. Discontinue if pregnancy occurs unless benefit clearly outweighs risk.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
GILENYA (fingolimod) requires first-dose monitoring for 6 hours due to risk of bradyarrhythmia; obtain baseline ECG, CBC, LFTs, and ophthalmologic exam. Avoid in patients with recent MI, unstable angina, stroke, or certain arrhythmias. Monitor for infections, especially cryptococcal meningitis and PML. Rebound disease activity may occur upon discontinuation. Lymphopenia is expected; monitor lymphocyte counts regularly.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take exactly as prescribed; do not skip doses without consulting your doctor.,You will need a 6-hour observation period after the first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) or visual changes immediately.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 2 months after stopping, as it may harm a fetus.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILENYA vs OFIRMEV, answered by our medical review team.
GILENYA is a Sphingosine 1-Phosphate Receptor Modulator that works by Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILENYA and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILENYA is: 0.5 mg orally once daily, with or without food. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILENYA and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILENYA is classified as Category C. FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at do. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.